These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 18364005)
1. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Apte RN; Voronov E Immunol Rev; 2008 Apr; 222():222-41. PubMed ID: 18364005 [TBL] [Abstract][Full Text] [Related]
2. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Apte RN; Dotan S; Elkabets M; White MR; Reich E; Carmi Y; Song X; Dvozkin T; Krelin Y; Voronov E Cancer Metastasis Rev; 2006 Sep; 25(3):387-408. PubMed ID: 17043764 [TBL] [Abstract][Full Text] [Related]
3. Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Apte RN; Krelin Y; Song X; Dotan S; Recih E; Elkabets M; Carmi Y; Dvorkin T; White RM; Gayvoronsky L; Segal S; Voronov E Eur J Cancer; 2006 Apr; 42(6):751-9. PubMed ID: 16530403 [TBL] [Abstract][Full Text] [Related]
4. Targeting the Tumor Microenvironment by Intervention in Interleukin-1 Biology. Voronov E; Apte RN Curr Pharm Des; 2017; 23(32):4893-4905. PubMed ID: 28606052 [TBL] [Abstract][Full Text] [Related]
5. Host-derived interleukin-1alpha is important in determining the immunogenicity of 3-methylcholantrene tumor cells. Elkabets M; Krelin Y; Dotan S; Cerwenka A; Porgador A; Lichtenstein RG; White MR; Zoller M; Iwakura Y; Dinarello CA; Voronov E; Apte RN J Immunol; 2009 Apr; 182(8):4874-81. PubMed ID: 19342666 [TBL] [Abstract][Full Text] [Related]
6. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression. Voronov E; Weinstein Y; Benharroch D; Cagnano E; Ofir R; Dobkin M; White RM; Zoller M; Barak V; Segal S; Apte RN Cancer Res; 1999 Mar; 59(5):1029-35. PubMed ID: 10070959 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Krelin Y; Voronov E; Dotan S; Elkabets M; Reich E; Fogel M; Huszar M; Iwakura Y; Segal S; Dinarello CA; Apte RN Cancer Res; 2007 Feb; 67(3):1062-71. PubMed ID: 17283139 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic approaches of IL-1 neutralization in the tumor microenvironment. Apte RN; Voronov E J Leukoc Biol; 2017 Aug; 102(2):293-306. PubMed ID: 28522598 [TBL] [Abstract][Full Text] [Related]
9. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Allavena P; Sica A; Garlanda C; Mantovani A Immunol Rev; 2008 Apr; 222():155-61. PubMed ID: 18364000 [TBL] [Abstract][Full Text] [Related]
10. IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation. Rider P; Carmi Y; Guttman O; Braiman A; Cohen I; Voronov E; White MR; Dinarello CA; Apte RN J Immunol; 2011 Nov; 187(9):4835-43. PubMed ID: 21930960 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-1--a major pleiotropic cytokine in tumor-host interactions. Apte RN; Voronov E Semin Cancer Biol; 2002 Aug; 12(4):277-90. PubMed ID: 12147202 [TBL] [Abstract][Full Text] [Related]
12. The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. Carmi Y; Voronov E; Dotan S; Lahat N; Rahat MA; Fogel M; Huszar M; White MR; Dinarello CA; Apte RN J Immunol; 2009 Oct; 183(7):4705-14. PubMed ID: 19752225 [TBL] [Abstract][Full Text] [Related]
13. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Langowski JL; Kastelein RA; Oft M Trends Immunol; 2007 May; 28(5):207-12. PubMed ID: 17395538 [TBL] [Abstract][Full Text] [Related]
14. Pre-interleukin-1alpha expression reduces cell growth and increases interleukin-6 production in SaOS-2 osteosarcoma cells: Differential inhibitory effect of interleukin-1 receptor antagonist (icIL-1Ra1). Palmer G; Trolliet S; Talabot-Ayer D; Mézin F; Magne D; Gabay C Cytokine; 2005 Jul; 31(2):153-60. PubMed ID: 15923123 [TBL] [Abstract][Full Text] [Related]
15. The efficacy of an IL-1alpha vaccine depends on IL-1RI availability and concomitant myeloid-derived suppressor cell reduction. Weiss T; Vitacolonna M; Zöller M J Immunother; 2009; 32(6):552-64. PubMed ID: 19483654 [TBL] [Abstract][Full Text] [Related]
16. Intracellular IL-1alpha-binding proteins contribute to biological functions of endogenous IL-1alpha in systemic sclerosis fibroblasts. Kawaguchi Y; Nishimagi E; Tochimoto A; Kawamoto M; Katsumata Y; Soejima M; Kanno T; Kamatani N; Hara M Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14501-6. PubMed ID: 16971486 [TBL] [Abstract][Full Text] [Related]
17. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes. Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103 [TBL] [Abstract][Full Text] [Related]
18. Intracellular interleukin-1 receptor antagonist type 1 antagonizes the stimulatory effect of interleukin-1 alpha precursor on cell motility. Merhi-Soussi F; Berti M; Wehrle-Haller B; Gabay C Cytokine; 2005 Nov; 32(3-4):163-70. PubMed ID: 16246569 [TBL] [Abstract][Full Text] [Related]
19. Different patterns of interleukin-1alpha and interleukin-1beta expression in organs of normal young and old mice. Hacham M; Argov S; White RM; Segal S; Apte RN Eur Cytokine Netw; 2002; 13(1):55-65. PubMed ID: 11956021 [TBL] [Abstract][Full Text] [Related]
20. [Interleukin 1 in host anti-tumor mechanisms]. Minato N Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 2):2105-10. PubMed ID: 3496853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]